- 201. Dose med or substance
- (UMLS (HL7) C1546603) =Intellectual Product =Specimen Source Codes;
| - 251. DOX/5-FU/TSPA
- (UMLS (NCI) C0280681) =Therapeutic or Preventive Procedure
|
- 202. Dose med or substance
- (UMLS (HL7) C1550627) =Substance =SpecimenEntityType;
| - 252. DOX/5-FU/TZT
- (UMLS (NCI) C0279453) =Therapeutic or Preventive Procedure
|
- 203. Dose response observed
- (UMLS (HL7) C1546996) =Idea or Concept =Causality Observations;
| - 253. DOX/5-FU/VBL
- (UMLS (NCI) C0279998) =Therapeutic or Preventive Procedure
|
- 204. Dose-Duration Alert
- [Proposed length of therapy differs from standard practice. ( HL7V3.0 )] (UMLS (HL7) C1555279) =Intellectual Product =Dosage problem;
=Dose-Duration Low Alert; Dose-Duration High Alert | - 254. DOX/5-FU/VNB
- (UMLS (NCI) C0281298) =Therapeutic or Preventive Procedure
|
- 205. Dose-Duration High Alert
- [Proposed length of therapy is longer than standard practice ( HL7V3.0 )] (UMLS (HL7) C1555281) =Intellectual Product =Dose-Duration Alert;
=Dose-Duration High for Indication Alert; | - 255. DOX/DPPE
- (UMLS (NCI) C0392975) =Therapeutic or Preventive Procedure ;
|
- 206. Dose-Duration High for Indication Alert
- [Proposed length of therapy is longer than standard practice for the identified indication or diagnosis ( HL7V3.0 )] (UMLS (HL7) C1555538) =Intellectual Product =Dose-Duration High Alert;
| - 256. DOX/DuP-941
- (UMLS (NCI) C0338273) =Therapeutic or Preventive Procedure ;
|
- 207. Dose-Duration Low Alert
- [Proposed length of therapy is shorter than that necessary for therapeutic effect ( HL7V3.0 )] (UMLS (HL7) C1555280) =Intellectual Product =Dose-Duration Alert;
=Dose-Duration Low for Indication Alert; | - 257. DOX/EDAM
- (UMLS (NCI) C0281407) =Therapeutic or Preventive Procedure ;
|
- 208. Dose-Duration Low for Indication Alert
- [Proposed length of therapy is shorter than standard practice for the identified indication or diagnosis ( HL7V3.0 )] (UMLS (HL7) C1555539) =Intellectual Product =Dose-Duration Low Alert;
| - 258. DOX/EM
- (UMLS (NCI) C0338295) =Therapeutic or Preventive Procedure
|
- 209. Dose-Interval Alert
- [Proposed dosage interval/timing differs from standard practice ( HL7V3.0 )] (UMLS (HL7) C1555278) =Intellectual Product =Dosage problem;
=Dose-Interval for Indication Alert; | - 259. DOX/EM/KCZ/VBL
- (UMLS (NCI) C0677757) =Therapeutic or Preventive Procedure
|
- 210. Dose-Interval for Indication Alert
- [Proposed dosage interval/timing differs from standard practice for the identified indication or diagnosis ( HL7V3.0 )] (UMLS (HL7) C1555540) =Intellectual Product =Dose-Interval Alert;
| - 260. DOX/ESDL/TSPA/VBL/ZDX
- (UMLS (NCI) C0280898) =Therapeutic or Preventive Procedure
|
- 211. Dosette
- [Special packaging that will help patients take their medications on a regular basis. ( HL7V3.0 )] (UMLS (HL7) C1553470) =Intellectual Product =Compliance Package;
| - 261. DOX/Ethiodized Oil
- (UMLS (NCI) C0280636) =Therapeutic or Preventive Procedure
|
- 212. dosimetry
- [assay procedure involving measurement of the radiation intensity of a radioactive sample. ( CSP )] (UMLS (NCI) C0034603) =Laboratory Procedure = ;
=scintillation spectrometry | - 262. DOX/FT/MITO
- (UMLS (NCI) C0279365) =Therapeutic or Preventive Procedure
|
- 213. dot blotting
- [ ] (UMLS (CSP) C0013064) =Laboratory Procedure
| - 263. DOX/FUDR
- (UMLS (NCI) C0278914) =Therapeutic or Preventive Procedure
|
- 214. DOTATOC
- [A chelated octreotide derivative with somatostatin activity. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of octreotide and chelated via dodecanetetraacetic acid (DOTA). Like octreotide, this edotreotide binds to somatostatin receptors (SSTRs), especially type 2, presence on the cell membrane of many types of neuroendocrine tumors. When labeled with nuclides, edotreotide conjugates could result in tissue specific cytotoxicity. ( NCI )] (UMLS (NCI) C0539568) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 264. DOX/FUDR/MITO
- (UMLS (NCI) C0280007) =Therapeutic or Preventive Procedure
|
- 215. Double
- [Consisting of or involving two parts or components, often in pairs. ( NCI )] (UMLS (NCI) C0205173) =Functional Concept
| - 265. DOX/FXM/TMX/TSPA/VBL
- (UMLS (NCI) C0279272) =Therapeutic or Preventive Procedure
|
- 216. DOUBLE BLIND
- [A clinical trial in which neither the medical staff nor the person knows which of several possible therapies the person is receiving. ( NCI )] (UMLS (NCI) C0013072) =Research Activity
| - 266. DOX/FXM/TSPA/VBL
- (UMLS (NCI) C0075860) =Therapeutic or Preventive Procedure
|
- 217. double layer electric potential
- [ ] (UMLS (CSP) C0599650) =Cell Function ;
| - 267. DOX/G-CSF
- (UMLS (NCI) C0281141) =Therapeutic or Preventive Procedure
|
- 218. double male syndrome
- [genetic disorder that produces tall and in many cases disturbed behavioral males due to XYY karyotype. ( CSP )] (UMLS (CSP) C0043379) =Congenital Abnormality; Disease or Syndrome =Chromosomal anomalies;
Sex Chromosome Abnormalities; syndrome; | - 268. DOX/G-CSF/IFF
- (UMLS (NCI) C0281618) =Therapeutic or Preventive Procedure
|
- 219. Double Minute 2 Protein
- [Inhibits p53 trans-activation, cell cycle arrest, and apoptosis. MDM2 binds p53 in the cell cycle at S/G2M phase and targets p53 for proteasome-mediated proteolysis. MDM2 also inhibits Rb protein and binds p14(ARF), ribosomal protein L5, and specifically to RNA. MDM2 gene expression is induced by DNA damage and regulated by the Ras-MAP kinase pathway. Some soft tissue sarcomas carry amplified MDM2 and overexpress MDM2 protein. (from SWISS-PROT Q00987, OMIM 164785, and NCI) ( NCI )] (UMLS (NCI) C0971008) HDM2;
MDM 2 Protein; MDM2; MDM2 Protein; p53 Binding Protein; p53-Binding Protein MDM2; Ubiquitin-Protein Ligase E3 MDM2; =Amino Acid, Peptide, or Protein; Biologically Active Substance ; | - 269. DOX/G-CSF/MP/PRED/VCR
- (UMLS (NCI) C0281131) =Therapeutic or Preventive Procedure
|
- 220. Double outlet right ventricle
- [Incomplete transposition of the great vessels in which both the AORTA and the PULMONARY ARTERY arise from the RIGHT VENTRICLE. The only outlet of the LEFT VENTRICLE is a large ventricular septal defect (VENTRICULAR SEPTAL DEFECTS or VSD). The various subtypes are classified by the location of the septal defect, such as subaortic, subpulmonary, or noncommitted. ( MSH )] (UMLS (ICD9CM) C0013069) =Congenital Abnormality; Disease or Syndrome ;
=COMPL TRANSPOS GREAT VES; | - 270. DOX/G-CSF/PRED/VCR
- (UMLS (NCI) C0281132) =Therapeutic or Preventive Procedure
|
- 221. DOUBLE PTERYGIUM
- [ ] (UMLS (ICD9CM) C0155157) =Disease or Syndrome
| - 271. DOX/G-CSF/TAX
- (UMLS (NCI) C0280906) =Therapeutic or Preventive Procedure
|
- 222. Double Strand Break Repair
- [Mechanisms of DNA repair associated with radiation damage. ( NCI )] (UMLS (NCI) C1158537) Double-Strand Break Repair;
=Genetic Function | - 272. DOX/G-CSF/TSPA
- (UMLS (NCI) C0280986) =Therapeutic or Preventive Procedure
|
- 223. double stranded RNA
- [RNA consisting of two strands as opposed to the more prevalent single-stranded RNA; most of the double-stranded segments are formed from transcription of DNA by intramolecular base-pairing of inverted complementary sequences separated by a single-stranded loop; some double-stranded segments of RNA are normal in all organisms. ( CSP )] (UMLS (CSP) C0035693) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance =Ribonucleic acid;
| - 273. DOX/GM-CSF
- (UMLS (NCI) C0280753) =Therapeutic or Preventive Procedure
|
- 224. Double Stranded RNA Virus
- [A virus that has double stranded RNA as its genetic material. ( NCI )] (UMLS (NCI) C1005582) dsRNA Virus;
=Virus | - 274. DOX/GM-CSF/IFF
- (UMLS (NCI) C0279011) =Therapeutic or Preventive Procedure ;
|
- 225. DOUBLING OF UTERUS
- (UMLS (ICD9CM) C0152240) =Congenital Abnormality ;
| - 275. DOX/HU
- (UMLS (NCI) C0281440) =Therapeutic or Preventive Procedure
|
- 226. Doubt raised
- (UMLS (HL7) C1547322) =Idea or Concept =Allergy Clinical Status;
| - 276. DOX/ICI D1694
- (UMLS (NCI) C0677753) =Therapeutic or Preventive Procedure ;
|
- 227. Douche
- [Douche ( HL7V3.0 )] (UMLS (HL7) C1698996) =Functional Concept =RouteByMethod;
=Douche, vaginal; | - 277. DOX/IFF
- (UMLS (NCI) C0278906) =Therapeutic or Preventive Procedure
|
- 228. Douche
- [washing of a body cavity or surface for therapeutic purposes by flowing solution which is inserted and then removed; drugs in the irrigation solution may be absorbed. ( CSP )] (UMLS (NCI) C0022100) =Therapeutic or Preventive Procedure =Therapeutic Interventions;
RouteByMethod =bronchoalveolar lavage; Irrigation, genitourinary; Irrigation, intralesional; Irrigation, intraocular; Irrigation, urinary bladder; Irrigation, intragastric; Irrigation, rectal; | - 278. DOX/IFF/MTP-PE Liposome/MTX
- (UMLS (NCI) C0281526) =Therapeutic or Preventive Procedure
|
- 229. Douche, vaginal
- [Douche, vaginal ( HL7V3.0 )] (UMLS (HL7) C1553210) =Spatial Concept =VaginalRoute;
Douche | - 279. DOX/IFF/MTX
- (UMLS (NCI) C0279209) =Therapeutic or Preventive Procedure
|
- 230. Doughnut Cell
- (UMLS (NCI) C0427519) =Laboratory or Test Result
| - 280. DOX/IFF/PRED/VCR
- (UMLS (NCI) C0279185) =Therapeutic or Preventive Procedure
|
- 231. Douglas Indian Association
- (UMLS (HL7) C1550847) =Population Group =NativeEntityAlaska;
| - 281. DOX/IFF/VCR
- (UMLS (NCI) C0279210) =Therapeutic or Preventive Procedure
|
- 232. Douroucoulis
- [A species in the family AOTIDAE, inhabiting the forested regions of Central and South America (from Panama to the Amazon). Vocalizations occur primarily at night when they are active, thus they are also known as Northern night monkeys. ( MSH )] (UMLS (CSP) C0003518) =Mammal
| - 282. DOX/IFF/VP-16
- (UMLS (NCI) C0677752) =Therapeutic or Preventive Procedure ;
|
- 233. Down syndrome
- [A disorder caused by the presence of an extra chromosome 21 and characterized by mental retardation and distinguishing physical features. ( NCI )] (UMLS (CSP) C0013080) =Congenital Abnormality; Disease or Syndrome ;
=Abnormalities, Multiple; Chromosomal anomalies; Arrieration mentale; syndrome; Chromosomal Disorders, Nervous System; | - 283. DOX/IFN-A
- (UMLS (NCI) C0338120) =Therapeutic or Preventive Procedure ;
|
- 234. Down-Regulated in Rhabdomyosarcoma LIM Protein
- [Members of the four-and-a-half-LIM domain (FHL) protein family, which are expressed in a tissue- and stage-specific manner, have been reported to function as transcriptional coactivators. Expression of DRAL (FHL2) results in enhancement of NF-kappaB activation. DRAL (FHL2) is a p53-responsive gene implicated in induction of apoptosis. DRAL may participate in a regulatory mechanism that coordinates cellular responses controlled by NF-kappaB transcription factor. (from J Biol Chem 2002;277:37045-53 and FEBS Lett 2002;521(1-3):165-9) ( NCI )] (UMLS (NCI) C1333635) FHL2;
Four and a Half LIM Domains 2; Four and a Half LIM Domains 2 Protein; =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 284. DOX/IL-2
- (UMLS (NCI) C0278683) =Therapeutic or Preventive Procedure
|
- 235. Down-Regulator of Transcription 1
- [Encoded by human DR1 Gene, TATA-Binding Protein-Associated Phosphoprotein represses both basal and activated levels of transcription. DR1 phosphorylation affects its interaction with TBP. The DR1 protein contains a histone fold motif at the amino terminus, a TBP-binding domain, and a glutamine- and alanine-rich region and represses transcription with DRAP1 by inhibiting pre-initiation complex formation through interaction with TFIID and DNA. The binding of DR1 repressor complexes to TBP-promoter complexes may establish a mechanism in which an altered DNA conformation, together with the formation of higher order complexes, inhibits the assembly of the preinitiation complex and controls the rate of RNA polymerase II transcription. (NCI) ( NCI )] (UMLS (NCI) C0170954) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 285. DOX/KCZ
- (UMLS (NCI) C0281712) =Therapeutic or Preventive Procedure
|
- 236. Down-Regulator of Transcription 1, TBP-Binding (Negative Cofactor 2) Gene
- [This gene is involved in repression of transcription. ( NCI )] (UMLS (NCI) C1333247) DR1;
DR1 Gene; =Gene or Genome ; | - 286. DOX/L-PAM/MePRDL
- (UMLS (NCI) C0281313) =Therapeutic or Preventive Procedure ;
|
- 237. Downward Ocular Deviation
- [Vertical strabismus in which there is permanent downward deviation of the visual axis of one eye. ( NCI )] (UMLS (NCI) C0152208) =Finding ;
| - 287. DOX/L-PAM/VM-26
- (UMLS (NCI) C0279939) =Therapeutic or Preventive Procedure
|
- 238. DOX-MTC
- [A formulation of doxorubicin bound to microscopic beads of activated carbon and iron (magnetic targeted carriers). Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids. The placement of a magnet on the body surface overlying a tumor site facilitates this carrier complex to deliver doxorubicin directly to the tumor, thereby prolonging the duration of the therapeutic effects while decreasing systemic toxicity. ( NCI )] (UMLS (NCI) C1134452) Doxorubicin-Magnetic Targeted Carrier Complex;
MTC-DOX; =Organic Chemical; Pharmacologic Substance | - 288. DOX/MeCCNU
- (UMLS (NCI) C0279380) =Therapeutic or Preventive Procedure
|
- 239. DOX-SL
- (UMLS (NCI) C0701182) =Organic Chemical; Pharmacologic Substance ;
| - 289. DOX/MeCCNU/SZC
- (UMLS (NCI) C0279268) =Therapeutic or Preventive Procedure
|
- 240. DOX/5-FU/GM-CSF/MTX
- (UMLS (NCI) C0280205) =Therapeutic or Preventive Procedure
| - 290. DOX/MePRDL
- (UMLS (NCI) C0796442) Doxorubicin/Methylprednisolone =Therapeutic or Preventive Procedure ;
|
- 241. DOX/5-FU/L-PAM
- (UMLS (NCI) C0279389) =Therapeutic or Preventive Procedure
| - 291. DOX/MITO
- (UMLS (NCI) C0279188) =Therapeutic or Preventive Procedure
|
- 242. DOX/5-FU/L-PAM/TMX
- (UMLS (NCI) C0279796) =Therapeutic or Preventive Procedure
| - 292. DOX/MITO/VBL
- (UMLS (NCI) C0052712) =Therapeutic or Preventive Procedure ;
|
- 243. DOX/5-FU/MeCCNU
- (UMLS (NCI) C0280593) =Therapeutic or Preventive Procedure
| - 293. DOX/MITO/VP-16
- (UMLS (NCI) C0280065) =Therapeutic or Preventive Procedure
|
- 244. DOX/5-FU/MITO/MTX
- (UMLS (NCI) C0279534) =Therapeutic or Preventive Procedure
| - 294. DOX/MP/MTX/PRED/VCR
- (UMLS (NCI) C0278924) =Therapeutic or Preventive Procedure
|
- 245. DOX/5-FU/MITO/SZC
- (UMLS (NCI) C0207828) =Therapeutic or Preventive Procedure
| - 295. DOX/MTX
- (UMLS (NCI) C0281523) =Therapeutic or Preventive Procedure
|
- 246. DOX/5-FU/MITO/TZT
- (UMLS (NCI) C0279447) =Therapeutic or Preventive Procedure
| - 296. DOX/MTX/PRED/VCR
- (UMLS (NCI) C0279197) =Therapeutic or Preventive Procedure
|
- 247. DOX/5-FU/MITO/VCR
- (UMLS (NCI) C0280592) =Therapeutic or Preventive Procedure
| - 297. DOX/MTX/VCR
- (UMLS (NCI) C0280061) =Therapeutic or Preventive Procedure
|
- 248. DOX/5-FU/MTX
- (UMLS (NCI) C0051571) =Therapeutic or Preventive Procedure ;
| - 298. DOX/PCB/PRED/VCR
- (UMLS (NCI) C0058827) =Therapeutic or Preventive Procedure ;
|
- 249. DOX/5-FU/MTX/PRED/TSPA/VBL
- (UMLS (NCI) C0279278) =Therapeutic or Preventive Procedure ;
| - 299. DOX/PCPZ
- (UMLS (NCI) C0280750) =Therapeutic or Preventive Procedure
|
- 250. DOX/5-FU/TMX/TSPA
- (UMLS (NCI) C0280699) =Therapeutic or Preventive Procedure
| - 300. DOX/PEG-ASP/PRED/VCR
- (UMLS (NCI) C0281219) =Therapeutic or Preventive Procedure ;
|